Are Tax Credits The Accelerator for U.S. EV Adoption?

 

Tax credits are shifting gears in the quest for U.S. EV adoption, playing a pivotal role in incentivizing electric vehicle (EV) production and boosting their adoption in the United States. With new supply chain rules affecting the eligibility for the $7,500 federal EV tax credit, only a select few models initially qualify, such as the Cadillac Lyriq, Chevy Bolt EV, and certain Tesla models. This move aims to reduce the auto industry’s reliance on China, which dominates around 70% of the global battery cell supply.

Despite the new restrictions, the majority of EVs sold in the U.S. still make the list, and tax credits for U.S. EV adoption are expected to continue pushing the market forward. More battery factories are set to become operational in eligible countries. Starting in 2024, EVs containing battery minerals sourced from China will be excluded from the tax credit. The impact of these changes on the EV market remains to be seen, but how will this affect the trajectory of U.S. EV adoption? 

Loren McDonald, Analyst at EVAdoption, points out the potential impact on non-US automakers and consumer choices and highlights the challenges in understanding the nuances of the policy.

Loren’s Thoughts:

“In the near term, the clean vehicle tax credit will likely not impact how many EVs that automakers produce. However, it is clearly driving non-US automakers to build EV factories in the US so that their EV models will qualify for the tax credit in the coming years and be much more price competitive. 

For consumers, the clean vehicle tax credit is like a Rubik’s Cube, and is extremely difficult to line up and understand all the nuances, including why their preferred EV may or may not qualify. Tax credits tend to not drive a significant increase in EV sales in the US but instead enable buyers to opt for a more expensive EV or lower their payments.

And with the new rules greatly limiting. Which vehicles qualify, it may simply shift consumers from buying a non-qualifying EV to one that does qualify for the $7,500 or $3,750 tax credit.”

 

Article written by Azam Saghir

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More